Navigation Links
CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
Date:12/3/2012

KING OF PRUSSIA, Pa., Dec. 3, 2012 /PRNewswire/ -- CSL Behring's parent company, CSL Limited (ASX: CSL), reaffirms the company's commitment to responsible business practice and sustainable development in its fourth Corporate Responsibility Report – Our Corporate Responsibility 2012. The report details CSL's performance across key corporate responsibility priority areas for the period July 1, 2011 through June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO

The priority areas include the Company's research into new and improved medicines, ensuring the safety and quality of its broad portfolio of therapies, providing a positive and healthy work environment for employees, behaving responsibly in the global marketplace, providing charitable support for communities in need around the world and minimizing the environmental impacts of its operations. Highlights of CSL's performance in these areas include:

  • Recognition of sustainable development and leadership by the FTSE4Good Index Series in 2011 and 2012 (FTSE4Good Index objectively measures the performance of companies that meet globally recognized corporate responsibility standards);
  • Research and Development investment of A$355 million dollars, with more than 30 clinical studies in operation across our portfolio of specialty and hemophilia products, breakthrough medicines and immunoglobulin-based products;
  • Economic contribution direct to local economies of more than A$4.2 billion, including global community (stakeholders and local communities) investment of A$35.4 million;
  • 2% growth in the total workforce with year-on-year reductions in recorded rates of lost time injury frequency and medical treatment injury frequency, including an 8% and 26% reduction from 2011, respectively;
  • 4% reduction in energy and water consumption and greenhouse gas emissions per unit of plasma production.

"CSL's reputation as one of the most innovative biopharmaceutical companies in the world and our continued growth are underscored by our commitment to conducting our business responsibly, and actively contributing to the well-being of our communities," said Dr. Brian McNamee, CEO and Managing Director of CSL Limited. "Our Corporate Responsibility Report for 2012 demonstrates this ongoing commitment."

About CSL Limited
Headquartered in Melbourne, Australia, CSL Limited (AUX: CSL) is a global biopharmaceutical company that develops, manufactures and markets biotherapies to prevent and treat rare and serious human diseases. CSL owns major facilities in Australia, Germany, Switzerland and the US, and employs over 11,000 people in more than 25 countries. For more information visit www.csl.com.au.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. For more information visit http://www.cslbehring.com/. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

View Our Corporate Responsibility 2012 at http://corporateresponsibility.csl.com.au/.

Contact:
Chris Florentz 
Manager, Corporate Communications
CSL Behring                                       
King of Prussia, PA                                                                            
+1 610 878 4316 

                           


'/>"/>
SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
2. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
3. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
4. Parent Project Muscular Dystrophy Endorses Senate Version of Prescription Drug User Fee Act After Patient Voice Strengthened
5. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
6. Parents Less Likely To Develop Colds, Carnegie Mellon Research Shows
7. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges St. Louis Parents to Vaccinate Preteens and Teens
8. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges Nashville Parents to Vaccinate Preteens and Teens
9. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges Minneapolis-St. Paul Parents to Vaccinate Preteens and Teens
10. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
11. Webcams Help Parents Keep Watch Over Their Babies During Hurricane Isaac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, ... 8th Day Software and Consulting, LLC , and named ... 8th Day Software, based in Tennessee , ... 8th Day expands EnvoyHealth,s service offerings for health care ... "In an interoperable ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the ... medical article to the newly revamped Cosmetic Town journal section, featuring ... transplant procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations ... literacy software tool, and the Cancer Patient Education Network (CPEN), an independent professional ... announce a new strategic alliance. , As CPEN’s strategic partner, HLI will ...
Breaking Medicine News(10 mins):